Drug intelligence / Profile preview

9D8 CAR-T

Development stage
Preclinical
Lead developer
Tongji University
Modality
CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

9D8 CAR-T is an experimental chimeric antigen receptor (CAR) T-cell therapy utilizing a nanobody-derived (VHH) binding domain specific for CD70. Developed for the treatment of renal cell carcinoma (RCC), the 9D8 clone was selected from alpaca immunization for its high affinity and specificity. Unlike traditional scFv-based CARs, the nanobody-based 9D8 CAR-T cells demonstrate enhanced cytokine production (IL-2, IFN-γ, TNF-α) and robust anti-tumor activity in xenograft models, including the ability to resist tumor re-challenge. The therapy aims to provide a long-lasting anti-tumor response by targeting CD70, which is highly expressed in RCC and associated with poor survival.

Other names
anti-CD70 9D8 CAR-Tanti-CD-70 9D8 CAR-Tanti-CD 70 9D8 CAR-T9D8-CAR-T
02

Targets

CD70 (Cluster of Differentiation 70)

Beyond the preview

Go deeper on 9D8 CAR-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 9D8 CAR-T.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call